Arrowhead Retained Earnings from 2010 to 2024

ARWR Stock

USD 18.54 0.26 1.42%

Arrowhead Pharmaceuticals Retained Earnings yearly trend continues to be relatively stable with very little volatility. Retained Earnings are likely to grow to about -877.3 M this year. Retained Earnings is the cumulative amount of net income that Arrowhead Pharmaceuticals retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

1998-03-31

Previous Quarter

-1.3 B

Current Value

-1.5 B

Quarterly Volatility

306.8 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Arrowhead Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arrowhead Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 15.1 M, Interest Expense of 20 M or Selling General Administrative of 79.1 M, as well as many indicators such as Price To Sales Ratio of 10.24, Dividend Yield of 0.0 or PTB Ratio of 4.8. Arrowhead financial statements analysis is a perfect complement when working with Arrowhead Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Arrowhead Pharmaceuticals Correlation against competitors.

To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.

Latest Arrowhead Pharmaceuticals' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Arrowhead Pharmaceuticals over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Arrowhead Pharmaceuticals' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arrowhead Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (1.03 B)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Arrowhead Retained Earnings Regression Statistics

	Arithmetic Mean	(492,389,795)
	Coefficient Of Variation	(62.77)
	Mean Deviation	245,555,343
	Median	(432,815,338)
	Standard Deviation	309,088,432
	Sample Variance	95535.7T
	Range	1B
	R-Value	(0.96)
	Mean Square Error	7123T
	R-Squared	0.93
	Slope	(66,678,862)
	Total Sum of Squares	1337499.2T

Arrowhead Retained Earnings History

	2024	-877.3 M
	2023	-923.4 M
	2022	-1 B
	2021	-820.8 M
	2020	-644.7 M
	2019	-503.8 M
	2018	-419.3 M

Other Fundumenentals of Arrowhead Pharmaceuticals

Retained Earnings Total Equity

Arrowhead Pharmaceuticals Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Long Term Debt	Property Plant Equipment	Good Will	Short Term Investments	Intangible Assets	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Accumulated Depreciation	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.78	0.04	-0.92	0.79	0.24	0.92	0.99	0.81	0.26	0.36	0.62	0.83	0.2	0.97	0.03	0.77	0.42	0.98	0.26	-0.22	0.93	0.11	0.72	0.72	0.26
Total Stockholder Equity	0.78		-0.4	-0.63	0.54	0.37	0.48	0.81	0.54	-0.14	0.39	0.55	0.48	0.25	0.66	0.17	0.8	0.37	0.74	0.26	-0.3	0.72	0.16	0.95	0.69	-0.14
Net Debt	0.04	-0.4		-0.17	0.32	-0.38	0.29	-0.06	0.02	0.12	-0.62	-0.07	0.43	-0.2	0.27	-0.28	-0.33	-0.03	0.09	-0.15	0.28	0.22	-0.16	-0.34	-0.29	0.13
Retained Earnings	-0.92	-0.63	-0.17		-0.78	-0.09	-0.9	-0.9	-0.75	-0.3	-0.23	-0.75	-0.83	-0.44	-0.92	-0.24	-0.63	-0.56	-0.95	-0.43	0.36	-0.86	-0.21	-0.55	-0.57	-0.29
Accounts Payable	0.79	0.54	0.32	-0.78		-0.14	0.76	0.77	0.81	-0.16	-0.17	0.52	0.97	0.16	0.81	0.02	0.28	0.33	0.78	0.27	-0.08	0.91	0.09	0.47	0.19	-0.16
Net Receivables	0.24	0.37	-0.38	-0.09	-0.14		0.12	0.21	-0.02	0.03	0.74	0.1	-0.15	0.03	0.1	0.0	0.4	0.21	0.15	0.04	-0.14	0.21	-0.03	0.44	0.41	0.03
Total Liab	0.92	0.48	0.29	-0.9	0.76	0.12		0.89	0.8	0.46	0.27	0.53	0.86	0.13	0.95	-0.06	0.6	0.36	0.91	0.2	-0.13	0.85	0.06	0.43	0.59	0.46
Total Current Assets	0.99	0.81	-0.06	-0.9	0.77	0.21	0.89		0.83	0.24	0.38	0.62	0.81	0.22	0.94	0.06	0.79	0.41	0.97	0.26	-0.25	0.9	0.14	0.74	0.73	0.24
Short Term Debt	0.81	0.54	0.02	-0.75	0.81	-0.02	0.8	0.83		0.08	0.26	0.51	0.83	0.11	0.77	-0.04	0.45	0.33	0.78	0.16	-0.08	0.78	0.03	0.51	0.43	0.08
Common Stock	0.26	-0.14	0.12	-0.3	-0.16	0.03	0.46	0.24	0.08		0.42	0.13	0.03	0.07	0.31	-0.02	0.4	0.13	0.3	0.08	-0.09	-0.03	0.02	-0.16	0.54	1.0
Current Deferred Revenue	0.36	0.39	-0.62	-0.23	-0.17	0.74	0.27	0.38	0.26	0.42		0.28	-0.13	0.19	0.19	0.15	0.61	0.28	0.3	0.18	-0.18	0.12	0.05	0.43	0.69	0.41
Long Term Debt	0.62	0.55	-0.07	-0.75	0.52	0.1	0.53	0.62	0.51	0.13	0.28		0.49	0.58	0.58	0.49	0.48	0.84	0.72	0.79	-0.52	0.55	0.02	0.48	0.48	0.13
Property Plant Equipment	0.83	0.48	0.43	-0.83	0.97	-0.15	0.86	0.81	0.83	0.03	-0.13	0.49		0.08	0.89	-0.09	0.34	0.3	0.83	0.16	-0.06	0.91	0.04	0.43	0.28	0.03
Good Will	0.2	0.25	-0.2	-0.44	0.16	0.03	0.13	0.22	0.11	0.07	0.19	0.58	0.08		0.15	0.96	0.17	0.52	0.31	0.64	-0.45	0.15	0.72	0.19	0.17	0.07
Short Term Investments	0.97	0.66	0.27	-0.92	0.81	0.1	0.95	0.94	0.77	0.31	0.19	0.58	0.89	0.15		-0.03	0.68	0.39	0.97	0.2	-0.15	0.93	0.08	0.62	0.65	0.31
Intangible Assets	0.03	0.17	-0.28	-0.24	0.02	0.0	-0.06	0.06	-0.04	-0.02	0.15	0.49	-0.09	0.96	-0.03		0.03	0.42	0.14	0.59	-0.42	-0.01	0.73	0.1	0.09	-0.02
Net Tangible Assets	0.77	0.8	-0.33	-0.63	0.28	0.4	0.6	0.79	0.45	0.4	0.61	0.48	0.34	0.17	0.68	0.03		0.32	0.75	0.2	-0.32	0.56	0.05	0.79	0.9	0.4
Long Term Debt Total	0.42	0.37	-0.03	-0.56	0.33	0.21	0.36	0.41	0.33	0.13	0.28	0.84	0.3	0.52	0.39	0.42	0.32		0.47	0.76	-0.42	0.37	-0.13	0.39	0.38	0.13
Capital Surpluse	0.98	0.74	0.09	-0.95	0.78	0.15	0.91	0.97	0.78	0.3	0.3	0.72	0.83	0.31	0.97	0.14	0.75	0.47		0.35	-0.29	0.9	0.15	0.67	0.71	0.3
Deferred Long Term Liab	0.26	0.26	-0.15	-0.43	0.27	0.04	0.2	0.26	0.16	0.08	0.18	0.79	0.16	0.64	0.2	0.59	0.2	0.76	0.35		-0.28	0.21	0.03	0.22	0.21	0.08
Accumulated Depreciation	-0.22	-0.3	0.28	0.36	-0.08	-0.14	-0.13	-0.25	-0.08	-0.09	-0.18	-0.52	-0.06	-0.45	-0.15	-0.42	-0.32	-0.42	-0.29	-0.28		-0.12	-0.26	-0.16	-0.2	-0.09
Long Term Investments	0.93	0.72	0.22	-0.86	0.91	0.21	0.85	0.9	0.78	-0.03	0.12	0.55	0.91	0.15	0.93	-0.01	0.56	0.37	0.9	0.21	-0.12		0.09	0.69	0.47	-0.03
Short Long Term Debt	0.11	0.16	-0.16	-0.21	0.09	-0.03	0.06	0.14	0.03	0.02	0.05	0.02	0.04	0.72	0.08	0.73	0.05	-0.13	0.15	0.03	-0.26	0.09		0.06	0.07	0.02
Net Invested Capital	0.72	0.95	-0.34	-0.55	0.47	0.44	0.43	0.74	0.51	-0.16	0.43	0.48	0.43	0.19	0.62	0.1	0.79	0.39	0.67	0.22	-0.16	0.69	0.06		0.7	-0.16
Net Working Capital	0.72	0.69	-0.29	-0.57	0.19	0.41	0.59	0.73	0.43	0.54	0.69	0.48	0.28	0.17	0.65	0.09	0.9	0.38	0.71	0.21	-0.2	0.47	0.07	0.7		0.54
Capital Stock	0.26	-0.14	0.13	-0.29	-0.16	0.03	0.46	0.24	0.08	1.0	0.41	0.13	0.03	0.07	0.31	-0.02	0.4	0.13	0.3	0.08	-0.09	-0.03	0.02	-0.16	0.54

Click cells to compare fundamentals

About Arrowhead Pharmaceuticals Financial Statements

Arrowhead Pharmaceuticals shareholders use historical fundamental indicators, such as Retained Earnings, to determine how well the company is positioned to perform in the future. Although Arrowhead Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Arrowhead Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arrowhead Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Retained Earnings	-923.4 M	-877.3 M
Retained Earnings Total Equity	-738.7 M	-701.7 M

Pair Trading with Arrowhead Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arrowhead Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arrowhead Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Arrowhead Stock

0.73

VALN

Valneva SE ADR

Pair Corr

Moving against Arrowhead Stock

0.48	KZR	Kezar Life Sciences	Pair Corr
0.31	MLYS	Mineralys Therapeutics,	Pair Corr

The ability to find closely correlated positions to Arrowhead Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arrowhead Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arrowhead Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arrowhead Pharmaceuticals to buy it.

The correlation of Arrowhead Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arrowhead Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arrowhead Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Arrowhead Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Arrowhead Stock Analysis

When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC